Want to join the conversation?
Diagnostic products maker $BDX's 1Q16 revenues grew 1.8%, which is in line with the prior guidance of 1-2% growth, reflecting solid underlying growth in Medical and Life Sciences segments. Adjusted EPS was $1.96, helped by solid underlying performance of the segments and earnings were ahead of the company's expectations.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.